| abstract |
The invention described herein relates to antibodies directed against the antigen TIM-1 and the use of such antibodies for the treatment of cancer (eg, renal and ovarian cancer). In particular, a fully human monoclonal antibody directed against the antigen TIM-1 is provided. Isolated polynucleotide sequences encoding heavy and light chain immunoglobulin molecules, and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly framework regions (FR) and / or complementarity determining regions ( CDRs) (specifically FR1-FR4 or CDR1-CDR3) are provided that correspond to contiguous heavy and light chain sequences. Hybridomas or other cell lines that express such immunoglobulin molecules and monoclonal antibodies are also provided. |